Sagimet Biosciences Inc.

SGMT | NASDAQ

Price Alert Chart Builder DCF Calculator

$11.14

+$0.34 (+3.15%)

Sep 22, 2026, 1:23 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+3.15%

(1D)

Rating

Updated: Aug 17, 2026

11.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $363.06M

1D Range

10.72 11.33

52W Range

4.50 11.45

Valuation (TTM)

PE -8.44

PB 1.37

EV/EBITDA -2.29

Valuation (NTM)

Forward PE N/A

Forward PEG -0.41

Price Target $18

Cash Flow

FCF Yield -11.7%

SBC Adj. FCF Yield -14.3%

SBC Impact -21.6%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -150.0% | 0.0%

Dil EPS 3Y | 5Y 0.0% | -7.3%

FCF 3Y | 5Y -23.5% | -20.8%

Returns

ROA -17.9%

ROE -32.0%

ROIC -20.4%

Financial Health

Net Cash

$240.13M

Current Ratio 45.02

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctio...

Sector Healthcare

Industry Biotechnology

Employees 16

IPO Date Jul 13, 2023

Website www.sagimet.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 12, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$18

Upside

+61.58%

Buy (5)

Hold (0)

Sell (0)

Analyst Details ➞